Justina Petrullo

Sarah Wall, MD, talks about how it’s important to consider patient age when treating older patients with cancer because it will impact so many of them and blood cancers act differently and can be more aggressive in older adults.

Lower-sodium oxybate (LXB) and sodium oxybate (SXB) were proven equally effective for cataplexy and excessive daytime sleepiness (EDS), despite LXB having 92% less sodium.

Aparna Balasubramanian, MD, discusses the importance of measurements such as heart rate variability, but also that there’s no such thing as just 1 biomarker that will give all information for high-risk patients with chronic obstructive pulmonary disease (COPD).

Andrew Ho, MD, talks about the importance of searching for what can be modified, such as closer transition to skilled nursing facilities, when working with patients who had pulmonary embolism (PE) and experienced readmission who had non-modifiable factors and comorbidities.

Jay Lee, MD, talks about financial toxicity in terms of the individual patient and in terms of the health system itself, especially in terms of non-small cell lung cancer (NSCLC) recurrence.

Patients with distant recurrent non–small cell lung cancer (NSCLC) had significantly better overall survival (OS) than patients who had de novo disease.

Older patients often face financial challenges on fixed incomes with different payer systems like Medicare, Sarah Wall, MD, The Ohio State University Comprehensive Cancer Center, says. Accessing treatment centers far away is difficult due to support system disruptions, leading to increased stress and financial strain.

Alma Habib, MD, The Ohio State University Comprehensive Cancer Center, talks about the fact that disparities are able to be recognized in leukemia/lymphoma care, but the questions of how to address these disparities remain.

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses why providers need to be wary when deciding whether patients with Crohn disease should switch from Humira (reference adalimumab) to an adalimumab biosimilar.

It is possible, if you lay the groundwork, to provide patients with acute leukemias with aggressive and effective therapies, while still allowing them to maintain quality of life, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.